Megna Michael R

CHIEF ACCOUNTING OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Sep 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$369K
Net Open-Market Flow
-$369K
Transactions
13
7 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 3, 2026Sell(S)5K$80.30$369K29K
Sep 1, 2026Option exercise(M)4K32K
Sep 1, 2026Option exercise(M)3K34K
Sep 1, 2026Option exercise(M)2K37K
Sep 1, 2026Option exercise(M)3K39K
Sep 1, 2026Tax withholding(F)6K$79.28$438K34K
Jul 15, 2026Grant(A)279$33.50$9K28K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 1, 2026Grant(A)4K$04K
Sep 1, 2026Grant(A)15K$015K
Sep 1, 2026Option exercise(M)3K$08K
Sep 1, 2026Option exercise(M)2K$05K
Sep 1, 2026Option exercise(M)3K$03K
Sep 1, 2026Option exercise(M)4K$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001464583-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about KNSA insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001464583-26-000008"
Ask your agent
Use Arkolith to summarize insider buying and selling at Kiniksa Pharmaceuticals International, plc
over the last 90 days and cite the filings.